Home › Funds › Vivo Capital, LLC › TRVI
Vivo Capital, LLC position in TRVI
TREVI THERAPEUTICS INC · Health Care
Vivo Capital, LLC reported holding 4,229,683 shares of TRVI (TREVI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$60.6M, representing 6.88% of its reported portfolio and ranking #2 among its reported holdings. Vivo Capital, LLC has disclosed TRVI holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's TRVI position evolved
Vivo Capital, LLC first disclosed a stake in TRVI in Q3 2024 at 1,612,903 shares (US$5.4M). The position peaked in Q2 2026 at 5,094,668 shares, worth US$95.0M. Across 9 filings, Vivo Capital, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 4,229,683 shares valued at US$60.6M — a reduction of -864,985 shares quarter over quarter.. Notable position changes include a 116% increase in Q4 2024 (shares rose 53% over the following quarter), a 29% increase in Q2 2025 (shares rose 67% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 1.61M | $5.39M | New |
| Q4 2024 | 3.49M | $14.37M | Add |
| Q1 2025 | 3.49M | $21.94M | Hold |
| Q2 2025 | 4.49M | $24.55M | Add |
| Q3 2025 | 5.09M | $46.62M | Add |
| Q4 2025 | 5.09M | $63.79M | Hold |
| Q1 2026 | 5.09M | $60.78M | Hold |
| Q2 2026 | 5.09M | $95.02M | Hold |
| Q3 2026 | 4.23M | $60.57M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vestal Point Capital, LP (US$57.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $246.59M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.94M sh · $185.37M · Q2 2026
- Vestal Point Capital, LP 3.10M sh · $57.81M · Q2 2026
- MPM BioImpact LLC 3.07M sh · $57.32M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 2.66M sh · $49.61M · Q2 2026
- Artia Global Partners LP 2.21M sh · $41.23M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $40.00M · Q2 2026
- First Light Asset Management, LLC 2.10M sh · $39.11M · Q2 2026
- Logos Global Management LP 1.88M sh · $35.06M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M sh · $33.57M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M sh · $32.50M · Q2 2026
- ORBIMED ADVISORS LLC 1.43M sh · $26.67M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held TRVI?
Vivo Capital, LLC has disclosed TRVI holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Vivo Capital, LLC's current position in TRVI?
As of Q3 2026, Vivo Capital, LLC holds 4.23M shares of TRVI (TREVI THERAPEUTICS INC), valued at $60.57M, representing 6.88% of its reported portfolio and ranking #2.
Has Vivo Capital, LLC been buying or selling TRVI?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC reduced its position in TRVI. The position peaked in Q2 2026 at 5.09M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.